Breast Cancer Treatment Pathway Navigator

Breast Cancer Treatment Pathway Navigator

Step-by-step decision support based on the ESMO Clinical Practice Guidelines for early (2024) and metastatic (2026) breast cancer

For healthcare professionals. This tool summarises guideline-based options to support, not replace, multidisciplinary team (MDT) discussion and clinical judgement. It is not endorsed by ESMO. Drug registration (e.g. SAHPRA) and funder approval vary; confirm availability locally.

Patient & tumour details

Suggested pathway

Preferred Option Consider Emerging Action

Sources

  • Loibl S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024;35(2):159–182. doi:10.1016/j.annonc.2023.11.016 (and ESMO Living Guideline updates).
  • de Azambuja E, et al. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2026 (last update May 2026; supersedes 2021 version).

Important

Content is a simplified, paraphrased summary of the guideline algorithms and key trials. It does not cover every scenario (e.g. pregnancy, male breast cancer, inflammatory disease, comorbidities, contraindications, dosing). Always check the full current guideline, the product information and local formularies. Last content review: November 2026.